Aberrant expression and reverse signalling of CD70 on malignant B cells. - Test2 - elhamkhani - TriplyDB

Aberrant expression and reverse signalling of CD70 on malignant B cells.

Aberrant expression and reverse signalling of CD70 on malignant B cells.

http://www.wikidata.org/entity/Q33872027

about

CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells Multiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178)Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75 Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies Expression of the immune regulation antigen CD70 in osteosarcoma.Pancreatic ductal adenocarcinoma: a review of immunologic aspects.Immunotherapy targets in pediatric cancer.CD70 expression patterns in renal cell carcinoma.Immunotherapy in allogeneic hematopoietic stem cell transplantation--not just a case for effector cells.Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.CD70 as a therapeutic target in human malignancies.CD70 is downregulated by interaction with CD27.Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.Investigational antibody-drug conjugates for hematological malignancies.Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.Therapeutic targeting of CD70 and CD27.Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.Signalling via CD70, a member of the TNF family, regulates T cell functions.Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma.Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans.Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma.Soluble CD27 induces IgG production through activation of antigen-primed B cells.Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma.Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells.

P2860

Q24292789-56114A97-58C8-406C-A66F-D7943E55D1A5 Q24681974-4AAC7F66-D1A1-4AE4-95B7-DFA7C3C0E10C Q28210406-FCE6CB9B-C0C2-47B7-BEE7-43C647C96954 Q28218575-2CCEEE1F-35B9-4DC6-8B67-2D67EF91473C Q33417191-223533DF-1436-45B6-935C-7DFC29314C03 Q33851887-5AFC6543-823C-4A82-8ABD-480146040FA7 Q34122802-068269CF-FBFA-42CC-8964-7F4B94F2D2B0 Q34353717-89A0302E-AA1F-44DC-9E3E-C70C89CD5EDF Q34923799-3FD20C2C-CD85-4DC5-9C34-D586468A15E9 Q35194116-4953963E-ACAD-48CD-A747-5C2FB025EF9B Q35870682-6E32DE6B-653A-4F7F-8C5F-59201FB8712E Q35971029-E006BE57-77D8-457A-8F20-C91739DA463B Q36028302-9922C29B-835C-47EE-8C31-88CAE17479CB Q36090223-A7991342-473D-4558-A5DD-0564F90DB106 Q36243608-550D4745-4742-4437-8C01-B63AE58B4D1C Q37082785-34FFAB2F-2434-4ECA-86FA-103AC93E5196 Q37112436-5E6F4922-7131-416E-9DE0-C2C5EA7EA824 Q37240065-0464367A-CF94-4D9C-A009-56045491B413 Q37818256-1C78A895-1D5C-4D5A-9303-84FFD31673EE Q38087390-AC6A8062-1E3A-448B-84F4-4B75D6359311 Q38633640-0795F6C4-3A08-45FC-8BCF-C4E3276859C5 Q38749841-22549F07-A30E-47E3-8EB5-94889B3E3A9A Q39233648-477DDA69-C8B9-451A-9BD8-8FC2955D4FAD Q40540340-C1966659-2859-4D33-9846-E999C582624D Q41346916-4AA860CF-313D-4EAB-B5CF-907F583D8ABC Q41971312-B95FE28C-6B44-4B33-8858-FD00692082E4 Q45240553-A7504322-573F-4863-9FD6-911564D88754 Q46203720-184B732E-6755-4A33-B8E9-4BCDCB97173F Q50027358-A20F7472-5D59-4D58-95D6-D9BAAE943832 Q50953796-3FAB8F82-106E-4ED7-927C-A3D15ADDF818 Q50992637-2D3AE52C-20AD-4C74-8E50-C88FAF99716C Q52026719-E8E2BB4F-4F2E-43AC-812C-FFEEDD90C67D Q52643503-8D6715AF-EADF-4EAE-AC6B-3C1A3B436149 Q53880896-9EE337CE-D046-43A5-B027-A263A1D900CB Q55006840-1C2D2962-B6BD-436C-8E14-5956052F1F00

P2860

Aberrant expression and reverse signalling of CD70 on malignant B cells.

http://www.wikidata.org/entity/Q33872027

description

1999 nî lūn-bûn

@nan

1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Aberrant expression and reverse signalling of CD70 on malignant B cells.

@ast

Aberrant expression and reverse signalling of CD70 on malignant B cells.

@en

type

label

Aberrant expression and reverse signalling of CD70 on malignant B cells.

@ast

Aberrant expression and reverse signalling of CD70 on malignant B cells.

@en

prefLabel

Aberrant expression and reverse signalling of CD70 on malignant B cells.

@ast

Aberrant expression and reverse signalling of CD70 on malignant B cells.

@en

P1433

Q33872027-E0A5E768-866E-4322-AC9D-6CA54038D248

P1476

Q33872027-26B508FF-67BD-41C7-A417-D76892AE12F0

P2093

Q33872027-038773CE-3717-4AD5-B94D-AEBEFA3B7E51

Q33872027-0D9EED52-89FF-4D5D-8D3D-596FEF8EF074

Q33872027-13CBC797-A916-4123-8F79-D8AD5B20997C

Q33872027-17068FB9-5A94-40E1-88F0-C36B4DFEEC5F

Q33872027-20B47E00-1D7A-4994-8D87-94B9A01DBA25

Q33872027-6E4BA1CA-D72A-45F4-8018-97A8F6A594FA

Q33872027-89D6A019-C867-4FE9-953D-9F97051719F3

P2860

Q33872027-17A514C1-4C99-477A-8B72-15623FEF8348

Q33872027-40137C96-7692-4E2E-B21C-C67115659698

Q33872027-4DE7620C-B3E0-42EB-B95E-D4AB7EAB5A7D

Q33872027-56BFF249-D79B-4051-8DB7-A0F782FDAC6F

Q33872027-5A02AA91-57F7-4D57-9260-486B8520AF16

Q33872027-7B6C9132-4C0B-4E9A-9F0F-2D9E9238222E

Q33872027-7EADAEE6-4F7D-435E-8FCF-8B4F0EA14B56

Q33872027-8007C0C4-3B01-421D-8BEE-F23A55BEB057

Q33872027-928723DB-89D4-4673-B57B-096F5843DC5D

Q33872027-B07E928F-CC6C-4DF9-9F5D-AFC2E808273E

P304

Q33872027-3D9D631C-2941-42CD-8C43-A05D739809D3

P31

Q33872027-8306D5C4-438A-43DB-B1BF-EF722D1D38BE

P356

Q33872027-32D7110D-0F12-4C65-9A0F-AC56DB38FC13

P407

Q33872027-58E9666A-6986-4EC4-A796-505CF1CF9F39

P433

Q33872027-C36ECE6D-94B4-44EC-A149-CB5E75AF3AE3

P478

Q33872027-FB34E47C-19D9-4BDE-BEEE-BEB9C757F8D7

P577

Q33872027-833D90EF-5EEE-41FA-839B-E6864EC7118A

P5875

Q33872027-7A2B510E-08EA-4959-848A-8E41FC0FE62B

P698

Q33872027-C712E633-93C3-4CDF-B14B-9B994087225D

P356

J.1365-2141.1999.01573.X

P1433

British Journal of Haematology

P1476

Aberrant expression and reverse signalling of CD70 on malignant B cells.

@en

P2093

Drillenburg P

http://www.w3.org/2001/XMLSchema#string

Lens SM

http://www.w3.org/2001/XMLSchema#string

Pals ST

http://www.w3.org/2001/XMLSchema#string

den Drijver BF

http://www.w3.org/2001/XMLSchema#string

van Lier RA

http://www.w3.org/2001/XMLSchema#string

van Oers MH

http://www.w3.org/2001/XMLSchema#string

van Schijndel G

http://www.w3.org/2001/XMLSchema#string

P2860

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells

CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase

Monoclonal antibody and ligand binding sites of the T cell erythrocyte receptor (CD2)

Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand

Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells.

T cell receptor signals enhance susceptibility to Fas-mediated apoptosis.

Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions.

Immune regulation by CD40 and its ligand GP39.

P304

491-503

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2141.1999.01573.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

1999-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229513568

http://www.w3.org/2001/XMLSchema#string

P698

10460611

http://www.w3.org/2001/XMLSchema#string